Austar Lifesciences (HKG:6118) Full Year 2024 Results
Key Financial Results
- Revenue: CN¥1.50b (down 15% from FY 2023).
- Net income: CN¥16.1m (up from CN¥32.6m loss in FY 2023).
- Profit margin: 1.1% (up from net loss in FY 2023). The move to profitability was driven by lower expenses.
- EPS: CN¥0.03 (up from CN¥0.064 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Austar Lifesciences shares are down 2.3% from a week ago.
Risk Analysis
It is worth noting though that we have found 2 warning signs for Austar Lifesciences (1 doesn't sit too well with us!) that you need to take into consideration.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.